Abviva, Inc. was established to develop and commercialize diagnostic and therapeutic products from a novel breast cancer growth inhibitory protein. Research scientists at the prestigious University of Michigan Cancer Center discovered a secreted protein produced in normal breast epithelial cells that inhibits the growth of breast cancer.

This discovery was developed into a diagnostic blood test for breast cancer, the Mammastatin Serum Assay (MSA). The MSA will be used to screen women for early detection of breast cancer. In clinical studies Mammastatin was found to be normally present in blood serum of healthy women and absent in women with breast cancer. Abviva intends to offer the MSA to women and their doctors through its wholly owned clinical reference laboratory, Biomedical Diagnostics, LLC.

Mammastatin was also shown to be a possible treatment for breast cancer. Palliative Stage IV women with terminal breast cancer were treated with an early therapeutic preparation of Mammastatin under Compassionate Use. Most of these women presented positive responses. Over half demonstrated regression of bone metastatic tumors. Lives were extended for over two years while on the Mammastatin therapy.

Mammastatin is normally present in healthy women and therefore comes “From Life”. It imparts a natural protection against breast cancer when present. When absent the risk of developing breast cancer increases. Abviva was named after this phenomenan. Abviva means “From Life”.

Protecting women from breast cancer before and after diagnosis is our vision. Our mission is to innovate, develop and commercialize diagnostic and therapeutic products from Mammastatin.